US009409982B2

(12) **United States Patent**
Kanda et al.

(10) **Patent No.: US 9,409,982 B2**
(45) **Date of Patent: *Aug. 9, 2016**

(54) **ANTIBODY COMPOSITION-PRODUCING CELL**

(71) Applicant: **KYOWA HAKKO KIRIN CO., LTD**, Tokyo (JP)

(72) Inventors: **Yutaka Kanda**, Machida (JP); **Mitsuo Satoh**, Machida (JP); **Kazuyasu Nakamura**, Machida (JP); **Kazuhisa Uchida**, Machida (JP); **Toyohide Shinkawa**, Machida (JP); **Naoko Yamane**, Machida (JP); **Emi Hosaka**, Machida (JP); **Kazuya Yamano**, Machida (JP); **Motoo Yamasaki**, Machida (JP); **Nobuo Hanai**, Machida (JP)

(73) Assignee: **KYOWA HAKKO KIRIN CO., LTD**, Tokyo (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/520,528**

(22) Filed: **Oct. 22, 2014**

(65) **Prior Publication Data**

US 2015/0112046 A1 Apr. 23, 2015

Related U.S. Application Data

(60) Continuation of application No. 13/672,006, filed on Nov. 8, 2012, now Pat. No. 8,895,266, which is a continuation of application No. 13/102,565, filed on May 6, 2011, now Pat. No. 8,329,443, which is a continuation of application No. 12/628,083, filed on Nov. 30, 2009, now abandoned, which is a continuation of application No. 11/218,473, filed on Sep. 6, 2005, now Pat. No. 7,741,442, which is a division of application No. 09/971,773, filed on Oct. 9, 2001, now Pat. No. 6,946,292.

(60) Provisional application No. 60/268,916, filed on Feb. 16, 2001.

(51) **Int. Cl.**

G01N 33/483	(2006.01)
A61D 19/04	(2006.01)
C07K 16/24	(2006.01)
C07K 16/18	(2006.01)
C07K 16/28	(2006.01)
C07K 16/30	(2006.01)
C07K 16/32	(2006.01)
C12N 9/04	(2006.01)
C12N 9/10	(2006.01)
C12N 9/90	(2006.01)
C12N 15/82	(2006.01)
C12P 21/00	(2006.01)
C07K 16/10	(2006.01)
C07K 16/44	(2006.01)

(52) **U.S. Cl.**

CPC ***C07K 16/241*** (2013.01); ***C07K 16/1063*** (2013.01); ***C07K 16/18*** (2013.01); ***C07K 16/2812*** (2013.01); ***C07K 16/2863*** (2013.01); ***C07K 16/2866*** (2013.01); ***C07K 16/2887*** (2013.01); ***C07K 16/3084*** (2013.01); ***C07K 16/32*** (2013.01); ***C07K 16/44*** (2013.01); ***C12N 9/0006*** (2013.01); ***C12N 9/1051*** (2013.01); ***C12N 9/90*** (2013.01); ***C12N 15/8245*** (2013.01); ***C12N 15/8257*** (2013.01); ***C12N 15/8258*** (2013.01); ***C12P 21/00*** (2013.01); ***C12P 21/005*** (2013.01); *C07K 2317/24* (2013.01); *C07K 2317/41* (2013.01); *C07K 2317/732* (2013.01); *C07K 2319/30* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,350,683	A	9/1982	Galfre et al.
4,721,777	A	1/1988	Uemura et al.
4,757,018	A	7/1988	Brown
4,816,567	A	3/1989	Cabilly et al.
4,849,509	A	7/1989	Thurin et al.
5,272,070	A	12/1993	Lehrman et al.
5,453,363	A	9/1995	Rudolph et al.
5,464,764	A	11/1995	Capecchi et al.
5,614,385	A	3/1997	Oppermann et al.
5,658,789	A	8/1997	Quaranta et al.
5,665,569	A	9/1997	Ohno
5,672,502	A	9/1997	Birch et al.
5,728,568	A	3/1998	Sullivan et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA	2424602	4/2002
CA	2481837	10/2003

(Continued)

OTHER PUBLICATIONS

Non-Final Office Action issued May 18, 2015, by the USPTO, in related U.S. Appl. No. 14/173,305.

Canadian Patent Office, Communication dated Dec. 18, 2014 issued in in counterpart Canadian Patent Application No. 2,704,600.

Gao et al; "Sensitivity of Heterozygous α1,6-Fucosyltransferase Knock-out Mice to Cigarette Smoke-induced Emphysema Implication of Aberrant Transforming Growth Factor-β Signaling and Matrix Metalloproteinase Gene Expression"; The Journal of Biological Chemistry; vol. 287; No. 20; May 11, 2012; pp. 16699-16708.

Japanese Patent Office, Communication dated Nov. 4, 2014 issued in counterpart Japanese Patent Application No. 2013-110926.

(Continued)

Primary Examiner — Robert M Kelly

(74) *Attorney, Agent, or Firm* — Sughrue Mion, PLLC

(57) **ABSTRACT**

The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependant cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.

7 Claims, 52 Drawing Sheets